London, Ontario (November 15, 2010): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that the Company will meet with several prospective partners who have expressed an interest in its lead oncology drug candidate COTI?2 at Europe's largest pharmaceutical partnering conference, BIO?Europe, taking place in Munich, Germany on November 15?17, 2010.
The objective of these meetings is to present compelling data on COTI’s potentially first?in?class and best?in?class oncology compound, COTI?2.During preclinical testing COTI?2 has demonstrated greater selectivity, an improved safety profile and superior pharmacokinetics in comparison to other Akt inhibitors.
COTI will meet with several prospective partners including executives from major pharmaceutical organizations at BIO?Europe.“We are delighted with the continued progress of our lead oncology candidate, COTI?2,” said Dr. Wayne Danter, CEO of COTI.“The results generated to date combined with the novel target and selectivity for Akt2 specifically will stimulate further discussions as we continue to evaluate our options for a licensing agreement for COTI?2.” Mr. Michael Barr, Vice President of Business Development and Marketing will represent COTI at BIO?Europe.
About COTI?2
COTI?2 is a novel small molecule that acts by inhibition of Akt/PKB (Protein kinase B) phosphorylation that leads to caspase?9 activation in cancer cells resulting in apoptosis or programmed cell death.In preclinical testing COTI?2 has demonstrated greater selectivity, an improved safety profile and superior pharmacokinetics in comparison to other Akt inhibitors.COTI?2 is easily synthesized and has good in vitro and in vivo efficacy against multiple cancers including small cell lung, non?small cell lung, colon, brain, ovarian, endometrial, triple negative breast and pancreatic. COTI?2 test results show it to be highly effective as a single agent therapy and as a combination therapy in a number of animal models of human cancers. COTI?2 differs from other cancer treatments in that other treatments involve the killing of healthy growing and dividing cells in the body resulting in significant toxic side effects while COTI?2 appears to target and destroy cancer cells only and has demonstrated low toxicity in normal human cells compared to human cancer cells. The combined scientific evidence indicates that COTI?2 is an ideal agent for combination therapy with current standard agents for a number of cancers. To request a non?confidential data package or discuss a partnership concerning COTI?2 please contact Michael Barr, Vice President of Business Development and Marketing at mbarr@criticaloutcome.com.
About Critical Outcome Technologies Inc. (COTI)
COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for accelerated identification and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective.COTI is focused on preparing its lead anti?cancer compound, COTI?2, for an Investigational New Drug filing in the USA in 2011.In addition to COTI?2, the company has a significant preclinical pipeline targeting large market opportunities such as:adult acute leukemia and other cancers, multiple sclerosis, HIV integrase, and Alzheimer’s disease.
For further information, please visit the website at www.criticaloutcome.com or contact:
Michael Barr Vice President of Business Development and Marketing 519?858?5157
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
